34 results about "INTESTINAL CARCINOMA" patented technology

The invention relates to a methylation biomarker for detecting colorectal cancer or colorectal adenoma. The methylation biomarker comprises any one gene of SDC2, COL4A2 and C9H9orf50 or any combination of the SDC2, the COL4A2 and the C9H9orf50. Wherein a methylation target detection region of the SDC2 gene is a full-length region of chr8: 96494012-96494130 or a partial region of the full-length region of chr8: 96494012-96494130; a methylation target detection region of the COL4A2 gene is a full-length region of chr13: 110306814-110306983 or a part of the full-length region of the chr13: 110306814-110306983; and the methylation target detection region of the C9H9orf50 gene is the full-length region of chr9: 129620291-129620374 or a part of the full-length region of chr9: 129620291-129620374. According to the kit, methylation signals related to intestinal cancer and adenoma in excrement samples can be more accurately detected through detection in different combination modes of the three markers, the early effective diagnosis rate of colorectal cancer patients can be increased, and therefore the survival rate of the patients is increased, and prognosis is improved.

An anti-HER2 antibody-drug conjugate for treating intestinal cancer in a subject. A use of the anti-HER2 antibody-drug conjugate in the preparation of a drug for treating intestinal cancer in a subject.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

The invention provides application of microbial metabolites in tumor immune response and an intestinal microbial metabolite screening method. A screening system is constructed by combining firefly luciferase with PD-1 / SHP-2, various intestinal microbial metabolites are independently co-cultured with the screening system, the screened microbial metabolites are glycodeoxycholic acid and taurocholic acid, and the influence of various metabolites on PD-1 pathway signal transduction is reflected by measuring the activity of luciferase. The invention constructs a reliable, rapid and effective screening method for discovering intestinal microbial metabolites influencing a PD-1 signal channel and evaluating the influence efficacy of the metabolites, and screening out metabolites having effects on intestinal cancer immune response, thereby providing an experimental basis for enhancing intestinal cancer treatment.

The present invention belongs to the field of microorganisms, and specifically relates to the use of Lactobacillus rhamnosus AFY01 and a product thereof in inflammatory colon cancer. Provided is a strain of Lactobacillus rhamnosus AFY01 with the deposit number of CGMCC No. 27362. The AFY01 can effectively alleviate weight loss in mice with colon cancer and colon shortening caused by intestinal inflammation and edema, reduce the colon coefficient of mice, reduce the visceral index and reduce the occurrence of intestinal tumors in mice, alleviate intestinal inflammation, and promote intestinal tumor cell apoptosis to slow down the development of colon cancer. By means of the present invention, the strain resources are expanded, thus providing technical support for the prevention and treatment of intestinal cancers.

The invention belongs to the technical field of biological medicine, and particularly relates to application of lovastatin combined with DHCR7 inhibitor AY9944 in preparation of medicine for treating colorectal cancer. The DHCR7 protein expression in the drug-resistant tumor tissue is obviously improved compared with that of normal tumor cells, and verification finds that the DHCR7 inhibitor AY9944 can specifically inhibit the drug resistance of colorectal cancer cells generating drug resistance, and further finds that when AY9944 and lovastatin are combined for use at a specific concentration ratio, the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited, and the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited. The two can play an obvious synergistic effect, so that the sensitivity of intestinal cancer cells to oxaliplatin is more effectively improved. Therefore, the combined medication mode provided by the invention can provide a new strategy reference for clinically overcoming the chemotherapy resistance of colorectal cancer.

Interleukin-23 receptor (IL23R) VHH antibodies are disclosed, as well as methods of making and using the same, e.g., for treatment of IL23-mediated diseases and disorders, including, e.g., gastrointestinal-related (Gl-related) diseases (e.g., inflammatory bowel disease (IBD) (e.g., ulcerative colitis (UC) or Crohn's disease (CD)), a colon cancer, a small intestine cancer, a gastric cancer, an irritable bowel syndrome, a gastrointestinal ulcer, a gut-associated infection (e.g., a Salmonella infection or a Clostridium difficile infection), celiac disease, or pathogenic inflammation).

The invention discloses a multi-omics non-invasive intestinal cancer risk assessment method based on pks + intestinal bacteria, cancer driver genes and methylated molecular clocks, which comprises the steps of excrement DNA sample extraction, primer design and screening, triple specificity verification, non-invasive detection and multi-omics quantitative scoring model, and detection of pks + escherichia coli in excrement. The pks + Escherichia coli can synthesize cytotoxin colicin, induce DNA double-chain breakage and chromosome instability in host cells, cause cell cycle arrest and finally cause cell death, key information can be provided for cancer prevention, diagnosis and precise treatment, and the application has the advantages that the application is wide in application range and high in practicability. In addition, deep understanding of the key cancer driver gene of the intestinal cancer is helpful for studying the occurrence and development mechanism of the intestinal cancer, a new therapeutic target can be provided for the intestinal cancer, new possibilities are provided for early discovery, risk assessment and monitoring of the intestinal cancer, the screening accuracy and sensitivity are further improved, and the screening method is suitable for popularization and application. And the method has the advantage of higher accuracy in risk assessment of intestinal cancer.

The present application relates to a kind of quinoline functional group nitrogen heterocyclic carbene ruthenium complex with multiple anticancer activity and its preparation method, the complex of the present application is prepared by 2-chloromethyl quinoline hydrochloride as starting compound, by with N-substituted imidazole or benzimidazole salt and metal exchange reaction, structural general formula is [LRu (p-cymene) Cl] (PF6). The present application nitrogen heterocyclic carbene ruthenium complex in lung cancer cell, cervical cancer cell, liver cancer cell, intestinal cancer cell, ovarian cancer cell and breast cancer cell cytotoxicity experiment all show strong cytotoxicity;In intestinal cancer cell, the present application nitrogen heterocyclic carbene ruthenium complex can effectively inhibit cell proliferation and migration;Mechanism research shows that the nitrogen heterocyclic carbene ruthenium complex mainly by interfering with mitochondrial membrane potential, induces cancer cell apoptosis;The present application nitrogen heterocyclic carbene ruthenium complex structure is variable, synthesis is convenient, stable, and has good application prospect.

The invention relates to seaweed dietary fiber rice and a preparation method thereof. The seaweed dietary fiber rice comprises the following components in percentage by weight: 5-25% of seaweed dietary fiber, 35-50% of rice flour, 20-30% of potato flour, 20-30% of tapioca flour and 0-0.5% of curdlan. On the basis of common rice, the seaweed dietary fiber is added, the dietary fiber deficiency under the dietary habit of people at present is supplemented, and the seaweed dietary fiber rice can promote mass proliferation of beneficial bacteria in the intestinal tract of the human body, promote intestinal tract movement, accelerate detoxification, prevent constipation, reduce the risk of intestinal cancer and the like.

The invention discloses application of a novel intestinal cancer detection kit of RBM15, and relates to the technical field of biological detection, the application of the RBM15 as the intestinal cancer detection kit in CRC molecular markers is characterized in that 36 pairs of CRC tissues and para-carcinoma samples are detected through qRT-PCR, expression data of RBM15 and corresponding serum tumor clinical indexes in 36 cases of CRC clinical tissues are analyzed through Spearman correlation, and the RBM15 and the expression data of serum tumor clinical indexes in the CRC clinical tissues are analyzed. Based on CRC in a TCGA database and expression data of a normal sample, an ROC curve of RBM15 and other tumor related indexes is drawn, an AUC value is calculated, and it is shown that the diagnosis efficiency is superior to that of part of traditional serum markers. As a novel CRC molecular marker, the RBM15 provided by the invention has remarkable advantages in the aspect of constructing a high-sensitivity and high-specificity detection kit, can be used for early diagnosis and prognosis evaluation, provides a new target for developing a treatment strategy of targeting m6A modification, and has wide clinical application and transformation prospects.

The invention belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound to preparation of a medicine for treating cancer, the structural formula of the benzothiazepine compound is shown in the formula I, and the cancer is selected from at least one of liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment, the compound shown in the formula I shows clear and different activities of resisting human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventor of the invention finds that the benzothiazepine compound as shown in the formula I has excellent activity on various different types of human tumors for the first time by performing activity screening on a small molecular skeleton, and provides an optional scheme for broad-spectrum anti-cancer drugs.

The invention relates to the field of traditional Chinese medicine preparations and the technical field of medicine analysis, in particular to a traditional Chinese medicine composition for treating liver cancer and intestinal cancer and a preparation method and a detection method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 200 to 300 parts of herba taraxaci, 200 to 300 parts of herba rabdosiae, 250 to 350 parts of ganoderma lucidum spore powder, 50 to 150 parts of solanum lyratum, 250 to 350 parts of centipede, 200 to 300 parts of radix scutellariae, 250 to 350 parts of oldenlandia diffusa, 250 to 350 parts of herba andrographitis, 400 to 500 parts of phellinus igniarius, 250 to 350 parts of radix tetrastigme, 50 to 200 parts of Chinese mahonia and 100 to 250 parts of agkistrodon halys. The traditional Chinese medicine composition has the effects of clearing away heat and toxic materials, removing blood stasis and phlegm, eliminating sores and removing stasis and is used for treating liver cancer and intestinal cancer.

The present application relates to the technical field of biology, and particularly relates to a preparation method and application of an anti-oncofetal antigen monoclonal antibody. The present application discloses a monoclonal antibody 12# with a heavy chain variable region shown in SEQ ID NO:1 and a light chain variable region shown in SEQ ID NO:2. The present application further discloses a preparation method and application of the antibody. The present application uses CEA extracted from liver cancer tissue after liver metastasis of intestinal cancer as an immunogen to immunize Balb / c mice, and uses hybridoma technology to screen and purify 12 strains of anti-CEA monoclonal antibodies. The obtained antibodies are labeled with horseradish peroxidase, and through cross pairing, one strain of antibody that can be used for labeling is selected and applied to detect CEA in human serum. The double antibody sandwich detection method established by using the labeled antibody has the advantages of high sensitivity, simple operation, short detection time and the like, and can provide key materials for subsequent development of commercial kits for CEA detection.

Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).

The invention provides application of ANKRD13A in preparation of drugs and diagnostic reagents for intestinal cancer, relates to the technical field of biomedicine, and is technically characterized by providing application of ANKRD13A as a therapeutic target in preparation of drugs for preventing and / or treating intestinal cancer. Close association between ANKRD13A and occurrence and development of the intestinal cancer is defined through a series of verification experiments. Clinical sample analysis shows that transcript abundance and protein expression level of ANKRD13A in a colon cancer tissue are remarkably lower than those in a normal colon tissue; the cell level verification proves that the mRNA and protein expression of ANKRD13A in the colon cancer cell line is obviously reduced compared with that of a normal colon epithelial cell line; animal experiments show that an Ankrd13a gene-deficient mouse is induced by AOM / DSS, the occurrence rate of colorectal tumors is higher, the number of the tumors is larger, and tumor tissues have medium-high-grade canceration characteristics along with abnormal expression of beta-Catenin, nuclear ectopic, increase of Ki67 positive cells and other malignant pathological expressions. The experimental results jointly prove that expression deletion or down-regulation of ANKRD13A is closely related to occurrence risk increase of intestinal cancer.

The invention discloses application of a ferroptosis inhibitor in preparation of a medicine for treating intestinal cancer related to colitis, and belongs to the technical field of medicines. The ferroptosis inhibitor is found to be capable of regulating intestinal epithelial cell activity, reducing intestinal epithelial cell inflammation and remarkably relieving various symptoms of an inflammatory cancer transformation model mouse, such as body weight rise, colitis DAI score reduction, colon shortening rise, obvious tumor size reduction and inflammatory factor level reduction. The preparation provided by the invention can be used for effectively improving the symptoms of mice with intestinal cancer related to colitis, a colitis cancer transformation prevention and treatment method based on ferroptosis inhibition is provided, and the living quality of patients is expected to be improved through a targeted intestinal epithelial cell ferroptosis pathway.

The invention is applicable to the technical field of biomedicine, and provides a serum protein marker, a kit and a detection method for early screening and diagnosis of pan cancer, the serum protein marker is RNASE4 protein, and the amino acid sequence of the serum protein marker is as shown in SEQ ID NO.1. The application finds that the serum concentration of the RNASE4 protein is remarkably related to various cancers for the first time, the RNASE4 protein can be used as an ideal marker for diagnosis of the pan-cancer, and the RNASE4 protein is provided as the pan-cancer marker, the matched kit and the detection method, so that the problems that the existing CA type marker is low in accuracy and sensitivity and easy to interfere are solved; high-specificity and high-sensitivity non-invasive early screening of intestinal cancer, pancreatic cancer, bladder cancer, breast cancer and ovarian cancer is achieved, the area under an ROC curve is larger than or equal to 0.85, detection operation is easy and convenient, and stability is good.

The present invention provides a culture medium for primary intestinal cancer cells, an in vitro culture method, and applications thereof. The culture medium comprises an MST1 / 2 kinase inhibitor; insulin; a Rho protein kinase inhibitor selected from at least one of Y27632, fasudil, and H-1152; an insulin-transferrin-selenium supplement; a glutamine additive; neuregulin 1; a bovine pituitary extract; basic fibroblast growth factor; R-spondin 1; prostaglandin E2; and B27. Compared to existing culture methods, in vitro culture using the culture medium of the present invention has higher amplification efficiency. Using this culture medium for primary intestinal cancer cells can maintain the morphological structure and pathological characteristics of the primary tissue, thereby improving the success rate and survival rate of primary intestinal cancer cell culture.

The invention discloses a culture method and application of high-secretion IFN-gamma CD4 + T cells, and relates to the technical field of immune cell culture. The cell culture medium disclosed by the invention is prepared from the following components: IL-2, IL-7, IL-15, IL-18, AB plasma, ConA, OKT3, CD28, an STING agonist, astragaloside, ginsenoside Rh2 and astragalus polysaccharide. The CD4 + T cells cultured by the culture medium disclosed by the invention are cultured in vitro for 15 days, the content of the CD4 + T cells is greater than 70%, and the CD4 + T cells secrete IFN-gamma at a higher level compared with the CD4 + T cells cultured by a common CD4 + T cell culture medium, and in addition, the in-vitro killing rate of the CD4 + T cells to HCT116 intestinal cancer cells reaches 95% or above due to the added STING agonist, astragaloside, ginsenoside Rh2 and astragalus polysaccharide.

The present invention provides a culture medium and a culture method for intestinal cancer organoids. The culture medium comprises an MST1 / 2 kinase inhibitor; a B27 additive; an N2 additive; insulin; A8301; human fibroblast growth factor-10; neuregulin-1; amphiregulin; at least one Rho protein kinase inhibitor selected from Y27632, fasudil, and H-1152; fetal bovine serum; basic fibroblast growth factor; insulin-like growth factor-1; forsklin; bovine pituitary extract; and fibroblast growth factor 7. Compared with existing culture methods, in vitro culture using the culture medium of the present invention has higher expansion efficiency. Cultivating intestinal cancer organoids using this culture medium can maintain the morphological structure and pathological characteristics of the original tissue, thereby improving the success rate and survival rate of intestinal cancer organoid culture.

Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).

The application belongs to the field of medicine, and particularly relates to application of a benzothiazepine compound in preparation of a cancer treatment drug, wherein the benzothiazepine compound has a structural formula as shown in formula I, and the cancer is at least one selected from liver cancer, intestinal cancer, bone cancer and lung cancer. According to a cell activity experiment of the application, it is found that the compound shown in formula I shows clear and different activities on human liver cancer cells, human lung cancer cells, human osteosarcoma cells and human colorectal cancer cells in vitro. The inventors of the application find, for the first time, through activity screening on a small molecule skeleton, that the benzothiazepine compound shown in formula I has excellent activity on various different types of human tumors, and the benzothiazepine compound provides an optional scheme for a broad-spectrum anticancer drug.

The purpose of the present invention is to provide a method for producing intestinal epithelial cells having functions close to those of a living organism from cells derived from intestinal cancer. Another purpose of the present invention is to provide a method for inducing differentiation from intestinal cancer-derived cells into intestinal epithelial cells having functions close to those of a living organism. Also provided is a culture medium that can be used in these methods.　Provided are: a method for producing intestinal epithelial cells, the method comprising air-liquid interface culture of cells derived from intestinal cancer in the presence of at least three or more selected from the group consisting of epidermal growth factors, TGFβ receptor inhibitors, Wnt signal enhancers, and cAMP signal activators, where the expression level of the CES1 gene is lower and the expression level of the CES2 gene is higher than when culture is performed in the presence of the at least three or more without performing air-liquid interface culture; and the use of the method.

A method for treating a microsatellite-stable (MSS) solid tumor is provided. The method includes administering a therapeutically effective amount of icariside I to a subject suffering from the MSS solid tumor. The method further includes administering a combination anti-cancer active agent to the subject, the combination anti-cancer active agent includes an immunotherapeutic agent (for example, a PD-1 / PD-L1 inhibitor and / or a CAR-T therapy product). A use of the icariside I in the preparation of a drug for treating or preventing the MSS solid tumor, particularly a MSS gastric cancer, a MSS intestinal cancer, a MSS lung cancer, a MSS pancreatic cancer, and a MSS hepatocellular carcinoma, and a kit including the same are further provided. A use of a combination of the icariside I and the immunotherapeutic agent in the preparation of a drug for treating or preventing the MSS solid tumor.

The invention belongs to the technical field of biological medicines, and particularly relates to a dipyrazolopyrimidine compound as well as a synthesis method and application thereof. The structure of the dipyrazolopyrimidine compound is as shown in the following formula (1). According to the invention, different fat heterocycles are introduced to the C5 site of a pyrimidine ring to inspect the size of the ring and the influence of substituent groups on the ring on the activity of the compound, and dipyrazolopyrimidine compounds 1-20 are designed and synthesized. Wherein the inhibition rate of the compound 2 is the highest and reaches 69.67%, and the compound 2 shows a remarkable inhibition effect. In addition, the compounds 4, 5, 13, 14, 15 and 17 also have high activity (the inhibition rate exceeds 30%). Therefore, the dipyrazolopyrimidine compound prepared by the invention is a KRASG12D inhibitor with relatively high activity and can be used for preparing medicines for treating pancreatic cancer, intestinal cancer and lung cancer. Formula (1).

The application discloses an eRNA molecular marker for assisting in diagnosing intestinal cancer and application thereof, characterized by that the eRNA molecular marker is eRNA42767, the nucleotide sequence of which is shown in SEQ ID NO. 1, and further provides application of the eRNA molecular marker in preparation of an intestinal cancer auxiliary diagnosis kit, wherein the kit comprises eRNA42767 fluorescent quantitative PCR specific amplification primers, the nucleotide sequence of an upstream amplification primer is 5'-CCTCTCTCTGGGACATGCCTA-3', and the nucleotide sequence of a downstream amplification primer is 5'-CACATGCGTAGAGATTCTTGCC-3', and the advantages are that early diagnosis of intestinal cancer patients at a molecular level can be realized conveniently, quickly and efficiently, the method has strong pertinence, high specificity and high sensitivity, and is favorable for early discovery and timely treatment of intestinal cancer.

The invention discloses application of rhodobryum harzianum in colorectal cancer diagnosis or prognosis, and belongs to the technical field of biomedicine.16SrRNA genome sequencing analysis finds that the content of rhodobryum harzianum in colorectal cancer tissue of a colorectal cancer patient is remarkably increased, the cancer promoting effect of the rhodobryum harzianum is further proved through a mouse AOM / DSS spontaneous tumor formation model, and the application of the rhodobryum harzianum in colorectal cancer diagnosis or prognosis is achieved. Compared with the prior art, the method provided by the invention has the advantages that the rhodobryum harzicola in a clinical sample is detected and a corresponding diagnosis model is established, so that the method has relatively high diagnosis efficiency and shows that the rhodobryum harzicola has important potential in clinical auxiliary diagnosis, treatment or prognosis evaluation of the colorectal cancer, a new way is provided for diagnosis, treatment or prognosis of the colorectal cancer, and the clinical application prospect is wide.

The invention relates to a preparation method of a ginsenoside Rg3 liposome loaded PD-L2 neutralizing antibody preparation, which comprises the following steps: dissolving ginsenoside Rg3 and phospholipid into a mixed organic solvent of absolute ethyl alcohol and trichloromethane according to a certain mass ratio, carrying out rotary evaporation to form a lipid membrane, carrying out vacuum drying, then adding a PBS (Phosphate Buffer Solution) of an alphaPD-L2 antibody, and carrying out vacuum drying to obtain the ginsenoside Rg3 liposome loaded PD-L2 neutralizing antibody preparation. And carrying out ultrasonic treatment and filtering with a filter membrane, so as to obtain the Rg3-lipo-alphaPD-L2 preparation. The medicine has great clinical application value, firstly, the awkward situation that a PD-L2 high-expression intestinal cancer patient has a poor curative effect on existing immunotherapy (such as a PD-1 / PD-L1 inhibitor) is broken through; 2, double-effect collaborative treatment of'synchronous inhibition of tumor metastasis' and'reversal of immune depletion ', which cannot be achieved by the existing therapy, is realized; and 3, the targeting of the medicine is enhanced to reduce the systemic toxicity and improve the therapeutic window.

The invention relates to the technical field of biological medicines, and provides application of a GOLGA7 inhibitor in preparation of a medicine for treating NRAS mutation positive tumors. The medicine disclosed by the invention takes the GOLGA7 gene as a target spot, and particularly utilizes a CRISPR / Cas9 gene editing technology or an RNAi interference technology to knock out or silence biological functions of the targeted GOLGA7 gene. The single guide RNA (sgRNA) and short hairpin RNA (shRNA) of the GOLGA7 gene provided by the invention can inhibit the expression level or activity of the GOLGA7 protein, so that the transport of NRAS mutant protein from Golgi apparatus to a cytoplasmic membrane is inhibited, the proliferation of NRAS mutation positive tumor cells is further inhibited, and the result is well verified in human and mouse tumor models. The gene is used as a target to develop a targeted intervention drug, and is expected to be applied to treatment of NRAS mutation positive tumors including hematologic tumors including leukemia, melanoma, intestinal cancer and the like.